Brain tumors, including brain metastases and gliomas, are among the worst
cancers in the world due to the ineffectiveness of existing treatment techniques.
Currently, many treatments are used to relieve pain and prolong survival time,
including chemotherapy, radiotherapy, and surgery, although all are destructive and
prolong the patient's lifespan by more than one year, and relapse is common even after
effective treatment. Numerous factors contribute to the failure of cancer treatments,
including physiological barriers like the Blood-Brain Tumor Barrier (BTB) and the
Blood Brain Barrier (BBB), which are difficult for existing macromolecularantitumor
medications to cross. These failure factors, together with the long-term success of
treatment, necessitate new developments in brain tumor treatments. Nanomedicine has
emerged as one of the most promising options for advancing or improving brain tumor
care. Targeted drug delivery with nanoparticles has the potential to significantly reduce
dosage, improve release characteristics, increase specificity and bioavailability,
lengthen the shelf life, and lessen toxicity and side effects. Some nanodrugs can cross
the BBB and BTB, which are major impediments to treating brain cancers. In this
chapter, we will examine the current state of the art, as well as the most unique and
exceptional innovations in treatment options, including a concise summary of
preclinical and clinical research on nanodrugs in brain tumor therapy.
Keywords: Brain tumor, Blood-brain barrier, Nanomedicine, Nanoparticles, Targeted drug delivery.
